stockrow
Friday 6 November 2026
Export ORGS’s income statement to Excel — free account
Orgenesis Inc.
ORGS Healthcare Biotechnology
Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023.
- Revenue
- +82.4%
- EPS
- −104.5%
- Free cash flow
- −317.9%
Quarter to December 2024, against a year earlier
0.35
0.05
−12.50%
Follow ORGS
Alert me
Orgenesis Inc. (ORGS) P/E ratio
Orgenesis Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 9.4× (November 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 2.0× | (60.08%) |
| FY2019 | 5.0× | — |
| FY2018 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| 34 more quarters | Free account |
Against its own ten years
Low 0.0×
High 9.4×
Ten-year median
0.0×
Current reading's percentile
84
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRIS Curis, Inc. compare | n/m |
| APRE Aprea Therapeutics, Inc. compare | n/m |
| LGVN Longeveron Inc. compare | n/m |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| EVGN Evogene Ltd. compare | n/m |
| XCUR Exicure, Inc. compare | n/m |
| AIM AIM ImmunoTech Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| ORGS Orgenesis Inc. | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)